Physician Views: Assessing competition in the idiopathic pulmonary fibrosis market

Physician Views: Assessing competition in the idiopathic pulmonary fibrosis market

Code: FW-20150506 | Published: May-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details








Late 2014/early 2015 witnessed a flurry of activity in the idiopathic pulmonary fibrosis (IPF) space: Roches $8.3 billion acquisition of InterMune - providing access to the IPF treatment Esbriet - and subsequent FDA approval of Esbriet and Boehringer Ingelheims competing therapy Ofev in mid-October.

In January, Ofev was approved for use in the EU, with Esbriets European label updated in February to reflect a mortality benefit demonstrated in Phase III studies (Esbriet having originally been approved in the region in 2011).

FirstWord Pharma has been tracking developments in the IPF market via a number of previous Physician View polls, focusing on the respective clinical profiles of Esbriet and Ofev, anticipated usage in the US market and launch of Ofev in the EU market.

With Esbriet and Ofev having now been available in the US market for over six months, and with the European IPF market evolving with the availability of Boehringer Ingelheims product and new labelling for Esbriet, we are asking pulmonologists based in the US and EU5 markets to provide their initial assessment of these two breakthrough drugs for IPF.








Specifically we are asking pulmonologists...

Of the newer treatments approved for IPF - Esbriet (pirfenidone) and Ofev (nintedanib) - which is your favoured drug (the one you prescribe the most) and why?
- Esbriet - based on clinical profile
- Esbriet - based on patient access programme
- Esbriet - based on price
- Esbriet - Other (please state)
- Ofev - based on clinical profile
- Ofev - based on patient access programme
- Ofev - based on price
- Ofev - other (please state)
- I use both products equally
- I have no choice in selecting either product but prefer Esbriet
- I have no choice in selecting either product but prefer Ofev

How satisfied are you with physician/patient access to Esbriet?
- Not at all satisfied
- Slightly satisfied
- Moderately satisfied
- Very satisfied
- Completely satisfied

How satisfied are you with physician/patient access to Ofev?
- Not at all satisfied
- Slightly satisfied
- Moderately satisfied
- Very satisfied
- Completely satisfied

In 12 months time, to what percentage of eligible IPF patients would you anticipate prescribing Esbriet to?

In 12 months time, to what percentage of eligible IPF patients would you anticipate prescribing Ofev to?






Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord